TABLE 4.

Analgesic dosing and effects for pubovaginal sling (PVS) and total vaginal hysterectomy (TVH)/PVS groups

Group PVS (groups 1 and 2)	ITO (n=58)	IVM (n=10)	P
Intrathecal morphine, mg	1.1±0.1	0	N/A
Intrathecal fentanyl, μg	49±6	0	N/A
Intraoperative fentanyl IV, μg	48±54	170±92
Intraoperative morphine IV, mg	0.3±0.4	0.8±2
Ketorolac dose in the first 24 h postop, mg	69.8±50.8	69.0±74.9	0.97
Ambulation in the first 12 h postop, n/n	58/58	7/10*	0.014
Group TVH/PVS (groups 3 and 4)	ITO (n=40)	IVM (n=13)	P
Intrathecal morphine, mg	1.0±0.2	0	N/A
Intrathecal fentanyl, μg	46±10	0	N/A
Intraoperative fentanyl IV, μg	45±41	302±114
Intraoperative morphine IV, mg	0.3±0.5	3.1±6.2
Ketorolac dose in the first 24 h postop, mg	103±53	32±61	<0.01
Ambulation in the first 12 h postop, n/n	39/40	10/13*	0.015

Data presented as mean ± SD unless otherwise indicated.

^*P<0.05. Intraoperative morphine and fentanyl: The doses of opioids given for intraoperative analgesia during general anesthesia. Intrathecal morphine and fentanyl: The doses of each opioid given as part of the intrathecal opioid (ITO) injection. Ambulation: The number of patients able to move out of bed in the first 12 h postoperatively (postop). IV Intravenous; IVM Intravenous morphine; N/A Not applicable